Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
ConclusionsBiosimilar filgrastim and pegfilgrastim as primary prophylaxis are cost-effective approaches to avoid FN events in patients with BC, NSCLC, or NHL at intermediate risk for FN in Austria, France, and Germany.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Austria Health | Breast Cancer | Cancer | Cancer & Oncology | Filgrastim | France Health | Germany Health | Lung Cancer | Lymphoma | Neulasta | Neupogen | Non-Small Cell Lung Cancer | Study